Document is current
Any future updates will be listed below
-
Authors
Womersley, Jacqueline S.
Roeh, Simone
Martin, Lindi
Ahmed-Leitao, Fatima
Sauer, Susann
Rex-Haffner, Monika
Hemmings, Sian M. J.
Binder, Elisabeth B.
Seedat, Soraya
-
Funding
Funding for this research was provided by:
South African National Research Foundation (South African Research Chair in PTSD, South African Research Chair in PTSD, South African Research Chair in PTSD, South African Research Chair in PTSD, South African Research Chair in PTSD)
South African Medical Research Council
- License Information
-
More Information
Article History
Received: 19 May 2022
Accepted: 23 September 2022
First Online: 5 October 2022
Declarations
:
: This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Stellenbosch University Health Research Ethics Committee (N10/11/370) and the Western Cape Education Department granted permission to access schools.
: Written informed consent was obtained from all the participants.
: EBB is co-inventor of the European patent application FKBP5: a novel target for antidepressant therapy European Patent# EP 1687443 B1 and receives a research grant from Böhringer Ingelheim to investigate FKBP5 as a candidate target in psychiatric disorders. The other authors declare that they have no competing interests.
